LOGIN  |  REGISTER
Amneal Pharmaceuticals
Compass Therapeutics

CVS Health to participate at the 45nd Annual Raymond James Institutional Investors Conference

February 21, 2024 | Last Trade: US$66.88 1.67 -2.44

WOONSOCKET, R.I., Feb. 21, 2024 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced that Executive Vice President and Chief Financial Officer Tom Cowhey will participate in a fireside chat with investors at the 45nd Annual Raymond James Institutional Investors Conference on March 5, 2024, at approximately 9:50 a.m. eastern time.

An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year.

About CVS Health

CVS Health® is the leading health solutions company, broadening access to care for millions of people nationwide. We improve the health of communities across America through our local presence, digital channels and with over 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. We support individuals with their health – whether that's managing health conditions, staying compliant with their medications or accessing affordable health services in the most convenient ways. Our goal is to create seamless connections across the health care system, simplifying the experience and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media.

 

Terns Pharmaceuticals

Stock Quote

Last Trade: US$66.88
Daily Change: -1.67 -2.44
Daily Volume: 15,611,840
Market Cap: US$84.270B

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page